

National Oesophago-Gastric Cancer Audit

Croydon Health Services NHS Trust

RM Partners West London, Cancer Alliance

Management of High Grade Dysplasia patients

Time period: 2018-22

| | | Cancer Alliance | National |
|---|-----|-----------------|----------|
| Number of High Grade Dysplasia patients in audit | 48 | | 1120 |
| | | Cancer Alliance | National |
| Method of Diagnosis | | | |
| – First diagnosis confirmed by second pathologist | N/A | 95.5% | 90.0% |
| Treatment planning | | | |
| – HGD plan discussed at MDT | N/A | 95.8% | 93.0% |
| – Treatment plan for active treatment | N/A | 85.0% | 82.0% |
| First treatment | | | |
| – Endoscopic therapy (such as endoscopic resection) | N/A | 85.0% | 78.0% |
| – Surveillance | N/A | 2.5% | 11.0% |

NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.

Management of oesophago-gastric cancer patients

Time period: 2020-2022

| | Organisation | | National |
|---|--------------|--------|----------|
| Number of oesophago-gastric (OG) cancer patients in audit | 67 | | 19,865 |
| Case ascertainment for OG cancer (%) | 75-84% | | |
| Method of Diagnosis | | | |
| – Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations | <10 | 12.0% | 13.1% |
| – Patients with referral source reported as unknown | 0 | 0.0% | 1.4% |
| Pre-treatment staging of cancer | | | |
| – Patients having staging CT scan recorded | 67 | 100.0% | 94.0% |
| Treatment planning | | | |
| – Patients having a plan for curative treatment | 40 | 59.7% | 37.2% |
| – Patients having a plan for non-curative treatment | 27 | 40.3% | 62.8% |
| – Patients with non-curative plans having chemotherapy or radiotherapy | N/A | | 34.7% |